RESUMEN
Primary hyperoxaluria is a rare genetic disorder characterized by oxalate overproduction, leading to kidney failure due to nephrocalcinosis, and is eventually responsible for systemic oxalosis. Bone impairment, secondary to oxalate deposits, is one of the many complications that may occur. Skeletal involvement can be difficult to diagnose because of lack of clinical symptoms and therefore needs to be confirmed by invasive testing, such as transiliac bone biopsy. If confirmed, bone oxalosis is the proof of disease severity and that combined liver-kidney transplantation should be performed.
Asunto(s)
Oxalato de Calcio/metabolismo , Hiperoxaluria Primaria/metabolismo , Ilion/patología , Nefrocalcinosis/metabolismo , Adulto , Biopsia , Densidad Ósea , Oxalato de Calcio/orina , Humanos , Hiperoxaluria Primaria/tratamiento farmacológico , Hiperoxaluria Primaria/genética , Hiperoxaluria Primaria/orina , Ilion/citología , Ilion/diagnóstico por imagen , Fallo Renal Crónico/metabolismo , Fallo Renal Crónico/terapia , Trasplante de Riñón , Masculino , Microrradiografía , Nefrocalcinosis/diagnóstico por imagen , Nefrocalcinosis/genética , Nefrocalcinosis/orina , Osteoblastos/patología , Piridoxina/uso terapéutico , Diálisis Renal , Transaminasas/genéticaRESUMEN
Avascular necrosis is an ischemic or cytotoxic necrosis of epiphyseal bone, responsible for joint pain, altered life quality and frequently affecting young patients. Avascular necrosis can be unifocal or multifocal, underlining the possibility of a systemic origin. Avascular necrosis involves the femoral head in more than 75% of cases. Although avascular necrosis is irreversible, many risk factors must be sought, including corticosteroid treatment, hypercholesterolemia, sickle cell disease or alcohol abuse. MRI imaging is the main exploration for the diagnostic and staging of the disease, and should be performed in unexplained hip pain in young patients with normal X-rays. In the earlier stages of the disease (stage I and II of the Arlet and Ficat classification), joint surface is preserved, and conservative treatment is recommended. In the more advanced stages (III and IV of the Arlet and Ficat classification), the articular surface collapses and joint arthroplasty is the main treatment. However, there are some recent therapeutic advances, based on mesenchymal stem cells, which may contribute, in the future, to improve the bad functional prognosis of the disease.